and now Barts Health are open and actively recruiting.
More sites across the UK will be opening
Details can now be found on clinical trial.gov. NCT02542787
Single dose escalation followed by multiple fixed dose administrations to assess short term safety and to determine whether spasticity improves.
VSN16R (Canbex name for molecule) oral capsules, daily or twice daily, total exposure 26 days.
Ages Eligible for Study: 18 Years to 70 Years
Genders Eligible for Study: Both
Accepts Healthy Volunteers: No
Have a confirmed diagnosis of MS
Have an Expanded Disability Status Scale (EDSS) ≤ than 6.5 at screening. Spasticity due to MS of at least 3 months duration with minimum mean score of >/=2 mASH
Acute MS relapse requiring treatment with steroids within 30 days of screening.
Initiation or discontinuation of MS disease modifying treatment (DMT) within 30 days of screening.
Receiving medications that would potentially interfere with the actions of the study medication or outcome variables
Significant renal and hepatic abnormalities
Previous history of other significant medical disorders
If are interested you need to get your GP/neuro to contact the trial centre.
VSN16R is the sixteenth drug made by a chemist called Cristina Visintin and is an R enatiomer compared to an S enantiomer (meaning a side chain can point forwards or backwards).
This has a unique mechanism of action, unlike any current anti-spastic drug.
Trial is called
A Phase II Proof of Concept (PoC), Double-Blind, Randomised, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of VSN16R for the Treatment of Spasticity in Subjects With Multiple Sclerosis.
or the CANBEX trial.
Canbex is a University College London Spin-Out Company aiming to develop VSN16R.
CoI: We are founders and consultants for Canbex